Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CDC25C | P30307 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239268 | 0.88 | KCNH2 (0.54) | KCNH2MEN1KMT2ANPC1CDC25C | |
| SCHEMBL26239278 | 0.84 | KCNH2 (0.39) | KCNH2CNR2 | |
| SCHEMBL26239253 | 0.82 | KCNH2 (0.61) | KCNH2MEN1KMT2ACDC25CTHRB | |
| SCHEMBL26240216 | 0.81 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL26239269 | 0.80 | KCNH2 (0.63) | KCNH2MEN1KMT2ACDC25CTHRB | |
| SCHEMBL26239282 | 0.76 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL10721556 | 0.71 | KCNH2 (0.62) | KCNH2MEN1KMT2ACDC25CTHRB | |
| SCHEMBL24601338 | 0.71 | KCNH2 (0.42) | KCNH2BLMCNR2SIGMAR1 | |
| SCHEMBL6572919 | 0.68 | KCNH2 (0.61) | KCNH2MEN1KMT2ACDC25CTHRB | |
| SCHEMBL3929250 | 0.68 | KCNH2 (1.00) | KCNH2CDC25CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885MEN1 4508/4885KMT2A 3188/4885 |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885MEN1 4508/4885KMT2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.